▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1984 by analyst upside · 2026-06-30
GMED
Globus Medical, Inc.
Healthcare · Market Cap $11B · P/E 19.6x
ANALYST PRICE TARGET
+29.4%
implied upside to consensus target
Current Price $83.94
Consensus Target $108.64
Bull Target $122.0
Bear Target $87.0
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
5
Hold
3
Sell
0
52-Week Low $51.79
52-Week High $101.4
YTD Return -3.8%
FUNDAMENTALS
Market Cap $11B
P/E Ratio (TTM) 19.6x
Forward P/E 16.3x
EPS (TTM) $4.28
PEG Ratio 1.49
Dividend Yield N/A
Revenue (TTM) $3.1B
Profit Margin 18.9%
52-WEEK RANGE
52-Week Low $51.79
52-Week High $101.4
Current Price $83.94
Bear Target $87.0
Bull Target $122.0
● Now $83.94 ● Target $108.64
TRADING DATA
Avg Volume 1.6M
YTD Return -3.8%
Analyst Count 11
Consensus Buy
Upside to Target +29.4%
Last Updated 2026-06-30

ANALYST SUMMARY

Globus Medical, Inc. (GMED) is currently trading at $83.94 with a Wall Street consensus price target of $108.64, implying potential upside of 29.4% over the next 12 months. 11 analysts currently cover GMED, with a consensus rating of Buy - 73% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $122.0, while the most cautious has a target of $87.0.

GMED operates in the Healthcare sector with a market capitalisation of $11B. The stock is down 3.8% year-to-date and is currently trading near the upper end of its 52-week range of $51.79 – $101.4.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

EHC +39.2%
Encompass Health Corporation
$10B · P/E 17.3x · Buy
SNN +16.5%
Smith & Nephew plc
$13B · P/E 21.0x · Hold
ALGN +17.2%
Align Technology, Inc.
$13B · P/E 30.0x · Buy
ENSG +39.3%
The Ensign Group, Inc.
$9B · P/E 26.6x · Buy
FMS +9.4%
Fresenius Medical Care AG
$12B · P/E 12.5x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for GMED, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Piper Sandler — Reiterated
Overweight → Overweight 2026-06-15 14% win rate (7 calls)
RBC Capital — Reiterated
Outperform → Outperform 2026-05-08 Building track record
Wells Fargo — Reiterated
Overweight → Overweight 2026-05-08 Building track record
Needham — Reiterated
Buy → Buy 2026-05-08 20% win rate (5 calls)
Wells Fargo — Reiterated
Overweight → Overweight 2026-02-26 Building track record
Barclays — Reiterated
Overweight → Overweight 2026-02-25 Building track record
Needham — Reiterated
Buy → Buy 2026-02-25 20% win rate (5 calls)
Needham ↑ Upgrade
Hold → Buy 2026-01-30 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
55
out of 100
Coverage depth
19/30
Consensus clarity
22/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →